On September 9, 2021 Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, reported a broad-based research collaboration with Boehringer Ingelheim International GmbH to use Twist’s proprietary antibody libraries to discover therapeutic antibodies against multiple targets provided by Boehringer Ingelheim (Press release, Boehringer Ingelheim, SEP 9, 2021, View Source [SID1234587473]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients," said Clive R. Wood, Ph.D., Senior Corporate Vice President and Global Head of Discovery Research at Boehringer Ingelheim. "We look forward to working with Twist on molecular targets in a broad range of disease areas," added Wood.

Under the terms of the agreement, Twist Biopharma, a division of Twist, will utilize its "Library of Libraries," a panel of synthetic antibody phage display libraries derived only from sequences that exist in the human body, to identify potential therapeutic antibody candidates. Twist and Boehringer Ingelheim will work together to validate and optimize any resulting new antibody candidates, which could be researched against a range of therapeutic areas. Boehringer Ingelheim retains exclusive worldwide rights to develop and commercialize any therapeutic antibodies discovered as part of the collaboration.

Twist will receive an upfront payment for each program entry. In addition, Twist has the potential to earn up to a total of $710 million in success-based clinical, regulatory and commercial milestone payments for the multiple target discovery programs.

"This discovery collaboration with Boehringer Ingelheim covering numerous targets truly illustrates the power of our antibody libraries. We have the ability to generate precise antibodies to a diverse range of targets, which together with Boehringer Ingelheim’s strength in drug development capabilities, could mean multiple new, more personalized treatments in the future for patients," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist.

On September 9, 2021 PharmaCyte Biotech presented Corporate presentation (Presentation, PharmaCyte Biotech, SEP 9, 2021, View Source [SID1234587523]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 9, 2021 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, reported that it will take part in two fireside chats, Baird’s 2021 Global Healthcare Conference, September 14-15 and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, September 20-23, 2021 (Press release, Cue Biopharma, SEP 9, 2021, View Source [SID1234608272]). Both conferences will be held virtually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the fireside chats, Cue Biopharma will provide a data update highlighting its lead clinical program, CUE-101, representative of the IL-2 based CUE-100 series for the treatment of second line and beyond patients with HPV+ recurrent/metastatic head and neck cancer. The discussion will also focus on the Company’s latest developments and pipeline progress.

Presentation Details:
Baird’s 2021 Global Healthcare Conference
Date and Time: Tuesday, September 14, 3:45 – 4:15 p.m. EDT
The webcasted fireside chat will be hosted on the conference website and available only to conference participants. Please visit View Source for more information.

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date and Time: Wednesday, September 22, 1:15 – 1:55 p.m. EDT
A live and archived webcast of the fireside chat will be available on the Events page in the Investors and Media section of the Company’s website at www.cuebiopharma.com. The webcast will be archived for 30 days.

About Baird’s 2021 Global Healthcare Conference
Baird’s 2021 Global Healthcare Conference brings institutional and private equity investors together with senior management from over 100 public and privately held companies. The conference will feature companies across the following sectors: Biotechnology, Healthcare Supply Chain & Pharma Services, Healthcare Information Technology, Life Sciences & Diagnostics, Medical Technology and Facilities & Services.

About Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Oppenheimer & Co. Inc. hosts multiple conferences a year covering many different industries. These conferences bring together corporate leaders, financial sponsors and institutional investors to explore market and sector trends. September 20-22 will feature presentations and one-on-one meetings in a virtual format with a select group of public companies in the Healthcare Life Sciences and MedTech arena. Thursday, September 23 will be the Private Company Day within the Summit and will feature a select group of emerging biotechnology and life science private companies. Investors will have the opportunity to meet virtually with management teams to discuss in detail key therapeutic programs in development and recent corporate updates.

On September 9, 2021 Acorda Therapeutics, Inc. reported a corporate restructuring to reduce costs and more closely align operating expenses with expected revenue (Press release, Acorda Therapeutics, SEP 9, 2021, View Source [SID1234587460]). The Company also announced changes to its management team.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Corporate Restructuring

As a result of the restructuring, the Company is reducing headcount by 15%. Most of the reduction in personnel will take place immediately, with the balance completed in the first quarter of 2022.

The Company expects to realize annualized cost savings of approximately $20 million from the headcount reductions and the outsourcing of certain operations, beginning in 2022. Acorda estimates that it will incur approximately $3.0 million of pre-tax charges for severance and other costs related to the restructuring, through the first quarter of 2022.

Management Changes

Lauren Sabella, currently Acorda’s Chief Commercial Officer, has been named Chief Operating Officer. She will have responsibility for Quality, Information Technology, Technical Operations, and Business Operations / Strategic Planning. Kerry Clem, Acorda’s Executive Vice President of Sales, Market Access, and Operations, has been named Chief Commercial Officer.

"We have made substantial progress over the past year, growing sales of Inbrija, maintaining Ampyra revenue to a substantial degree, and retiring our short-term debt. We have achieved these outcomes despite the significant impact of the pandemic on our business. When the pandemic subsides, we believe that we will have the opportunity to accelerate Inbrija’s trajectory, as in-person interactions with health care providers and patients return to more normal levels. The headcount reductions and structural changes we have made will enable us to operate more efficiently and further align our expenses with revenue, while continuing to grow Inbrija sales," said Ron Cohen, M.D., Acorda’s President and Chief Executive Officer. "We are deeply grateful to the associates who are leaving Acorda for their commitment, hard work, and many contributions."

September 9, 2021 Boston Scientific Corporation reported that it will host a meeting with the investor community to review its financial goals and long-term growth strategies on Wednesday, September 22, 2021, from 8:30 a.m. – 12:30 p.m. EDT (Press release, Boston Scientific, SEP 9, 2021, View Source [SID1234587476]). Company leaders will also provide business unit market overviews, pipeline updates and spotlight key products from the company’s Cardiovascular, MedSurg and Rhythm and Neuro segments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The meeting will be held in hybrid format, live in Boston as well as a simultaneous webcast. Investors and other interested parties may register for the live meeting or webcast by visiting the events and presentations section on the company’s investor website at View Source A replay and summary materials from the presentations will also be available online for approximately one year following the event.